Abstract:Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. In this paper, we describe a series of novel cyclic peptides derived from an mRNA display screen which inhibit the protein–protein interaction between PCSK9 and LDLR. Using a structure-based drug design approach, we were able to modify our original screening lead 2 to optimize the potency and metabolic stability and minimize the molecular weight to provide novel bicyclic next-generation PCSK9 inhibitor peptides such as 78. These next-generation peptides serve as a critical foundation for continued exploration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01084?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01084</a>.Representative LC traces for key molecules in the paper, sample IC50 curves for LDLR-FRET and Alexa-FRET assay control peptide, and raw concentration versus time profiles for molecules tested in Mouse IV PK 3D PDB files for each of the new crystal structures have also been uploaded; PDB codes for the crystal structures shown in the paper are as follows: compound 30, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIB">6XIB</a>; compound 40, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIC">6XIC</a>; compound 51, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XID">6XID</a>; compound 78, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIE">6XIE</a>; and compound 84, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIF">6XIF</a>; and authors will release the atomic coordinates and experimental data upon article publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_001.pdf">PDF</a>)6xib (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_002.pdb">PDB</a>)6xic (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_003.pdb">PDB</a>)6xid (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_004.pdb">PDB</a>)6xie (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_005.pdb">PDB</a>)6xif (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_006.pdb">PDB</a>)This article has not yet been cited by other publications.

Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design

Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity

Strategies for Improving Peptide Stability and Delivery

Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis

PCSK9 Inhibition: From Current Advances to Evolving Future

Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

Changes in pulmonary calcitonin gene-related peptide and protein gene product 9.5 innervation in rats infected with Mycoplasma pulmonis

Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study

In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications

Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity–Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor–Binding Enhancement

Development of Innovative Antiatherosclerotic Peptides through the Combination of Molecular Modeling and a Dual (Biochemical‐Cellular) Screening System

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Increased Half-Life and Enhanced Potency of Fc-modified Human PCSK9 Monoclonal Antibodies in Primates.

PCSK9 Inhibition-Based Therapeutic Approaches: an Immunotherapy Perspective.

Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability

Unraveling the Potential of Hypericin: A Novel Approach to Targeting PCSK9 Mutations in Cholesterol Management

Exploiting Complex-Type N-Glycan to Improve the in Vivo Stability of Bioactive Peptides